Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
10.7534/j.issn.1009-2137.2014.05.050
- Author:
Jing WANG
1
;
Jin ZHOU
1
;
Hui-Fei ZHENG
1
;
Zheng-Zheng FU
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Provincial Institute of Hematology, Suzhou 215000, Jiangsu Province, China.
2. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Provincial Institute of Hematology, Suzhou 215000, Jiangsu Province, China. E-mail: zhenzhenfu@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Antimetabolites, Antineoplastic;
pharmacology;
Azacitidine;
analogs & derivatives;
pharmacology;
Graft vs Leukemia Effect;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
immunology;
therapy;
Quality of Life;
T-Lymphocytes, Cytotoxic;
T-Lymphocytes, Regulatory;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2014;22(5):1448-1452
- CountryChina
- Language:Chinese
-
Abstract:
Based on the representative articles in recent years, the different mechanisms of decitabine on immune regulation in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT) are summarized. Decitabine improves the expression of WT1 gene to stimulate specific cytotoxic T cells which can enhance graft versus leukemia effect (GVL) and improve the expression of FOXP3 gene to stimulate regulatory T cells so as to inhibit the acute graft versus host disease (GVHD). Through the above-mentimed mechanisms, decitabine can improve both therapeutic effect and quality of life in the patients with AML after allogeneic HSCT.
